Our vision is to improve the lives of patients and families suffering from rare muscle disorders, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), by building the world’s leading muscle-focused, precision medicine company. In less than four years, we have matured into a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing drugs to treat patients with rare muscular disorders for which there is significant unmet medical need.
Our lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). This drug candidate, EDG-556, is currently in a Phase 1 clinical trial.
(Note: Edgewise Therapeutics upsized its IPO at pricing on March 25, 2021, by pricing 11 million shares, up from 10 million in the prospectus, at $16 – the top of its $14-to-$16 range – to raise $176 million.)
|Address||3415 Colorado Ave. Boulder, CO 80303|
|Phone Number||(303) 735-8373|
|View Prospectus:||Edgewise Therapeutics|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-17.12 mil (last 12 months)|
|Price range||$16.00 - $16.00|
|Est. $ Volume||$176.0 mil|
|Manager / Joint Managers||J.P. Morgan/ Goldman Sachs/ SVB Leerink|
|Expected To Trade:||3/26/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|